AFT-50 EndoMAP Targeted Agents and/or Immunotherapy with Atezolizumab for Endometrial Cancer - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if certain experimental drug combinations are safe and effective options for people who have recurrent or persistent endometrial cancer (cancer that has come back after treatment or does not respond to treatment).

What is the Condition Being Studied?

Recurrent or Persistent Endometrial Cancer

Who Can Participate in the Study?

Adults ages 18+ who:

Are diagnosed with endometrial cancer
Did not respond to previous treatment or had their cancer return after treatment
Have not received more than 2 lines of previous therapy (can include chemoradiation, chemotherapy and/or biologic therapy, or maintenance/consolidation therapy - hormonal therapies like aromatase inhibitors or tamoxifen do not count as a line of therapy)

For more information about this study, contact the study team at william.s.andrews@duke.edu.

Age Group

Adults

What is Involved?

If you choose to join this study, you will be assigned a specific study regimen based on specific biomarkers we find in a sample of your tumor. Depending on our findings, you will get one of the following study drug regimens: